LY5, a small molecule inhibitor that antagonizes constitutive and inducible STAT3 activation, was shown to inhibit tumor cell migration and angiogenesis and to induce apoptosis in medulloblastoma, osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma cells [36–39]. This evidence concerns the gene STAT3 and osteosarcoma.